Loading
A phase 3 trial of Cladribine, Cyclophosphamide and Rituximab in Leukaemia, run by Hoffmann-La Roche, completed.
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT00718549 by Hoffmann-La Roche, with 128 participants recorded, started 2009-07-21 and reaching its primary completion in 2015-09-14. Interventions recorded: Cladribine, Cyclophosphamide, Rituximab. Conditions recorded: Lymphocytic Leukemia, Chronic.
Linked to the drug Cladribine because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
128 enrolled.
Median and Upper Limit could not be calculated due to insufficient number of participants who had an event.; Figures from the ClinicalTrials.gov results section (first posted 2018-08-20), not from a publication · 95% CI 1.9 to NA · 95% CI 2.2 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Fee Survival (PFS) Assessed According to the NCI Revised Guidelines for the Diagnosis and Treatment of CLLprimary | Maintenance Arm: Rituximab | 33 | Median and Upper Limit could not be calculated due to insufficient number of participants who had an event.; Figures from the ClinicalTrials.gov results section (first posted 2018-08-20), not from a publication | - | - | link |
| Observation Arm: No Intervention | 33 | 2.1 years | ||||
| All Randomized Participants | 66 | 3.1 years |
Shares Cladribine, Leukaemia (all types), Cyclophosphamide and the tag pipeline.
Shares Rituximab, Leukaemia (all types) and the tag pipeline.
Shares Cladribine and the tag pipeline.
Shares Leukaemia (all types), Cyclophosphamide and the tag pipeline.
Shares Rituximab, Cyclophosphamide and the tag pipeline.
Shares Rituximab, Cyclophosphamide and the tag pipeline.
Shares Rituximab, Cyclophosphamide and the tag pipeline.
Shares Rituximab, Cyclophosphamide and the tag pipeline.